Oncology/Hematology
Lung Cancer
More in Lung Cancer
News, features, and commentary about cancer-related issues
News, features, and commentary about cancer-related issues
PD-1/PD-L1 inhibitors singled out for association
News, features, and commentary about cancer-related issues
A look back at some of the newsworthy developments of 2024
Largest survival benefit observed in patients who entered a cessation program within 6 months
-- News, features, and commentary about cancer-related issues
Debate highlights pros and cons of the new recommendation
Osimertinib plus ramucirumab in first line shows 9-month PFS advantage over EGFR inhibition alone
Study raises questions about how to assess patient risk, experts say
News, features, and commentary about cancer-related issues
Latest negative results emphasize "critical" aspect of immunotherapy timing
EGFR inhibitor now indicated for unresectable stage III disease following chemoradiotherapy
Actual rates for 2021 lagged behind projections
